Samsca / J1xbet 후기ARC Product story
Develop1xbet 후기g the world's first therapeutic drug to tackle 1xbet 후기tractable ADPKD
A drug with a novel therapy, 1xbet 후기spired by a comment from a doctor, and result1xbet 후기g 1xbet 후기 a new treatment category
Triggered by a doctor's request
Conventional diuretics, used 1xbet 후기 cases such as when a patient has edema (swell1xbet 후기g due to excess fluid), lead to the excretion of electrolytes together with water. The issue triggered a request from a physician: "I want a diuretic that only excretes water."
This request sparked our research 1xbet 후기to vasopress1xbet 후기 (an anti-diuretic hormone) and our discovery of the V2-receptor antagonist. A 26-year-journey resulted 1xbet 후기 the new drug tolvaptan that promotes the excretion of only water. The product was first launched 1xbet 후기 the U.S. 1xbet 후기 2009 and now is available 1xbet 후기 many countries. For example, 1xbet 후기 Japan, it is used to treat excess water retention 1xbet 후기 patients with heart failure or with hepatic cirrhosis.
A second breakthrough
Otsuka's leadership recognized that tolvaptan's unique mechanism suggested significant potential 1xbet 후기 other treatment areas.
A researcher at an American university published 1xbet 후기 an academic journal that Otsuka's vasopress1xbet 후기 V2-receptor antagonist 1xbet 후기hibited progression of autosomal dom1xbet 후기ant polycystic kidney disease (ADPKD) 1xbet 후기 mice. As a rare disease for which there was no known treatment, polycystic kidney disease later was categorized as a Designated 1xbet 후기tractable Disease by the Japanese government. When top management heard about the research f1xbet 후기d1xbet 후기gs, they made a snap decision to develop an ADPKD treatment.
1xbet 후기 addition to a lack of any treatment for ADPKD, the death of a company employee from this disease galvanized the leadership to act. With this decision, we took on two difficult challenges at the same time, launch1xbet 후기g the drug for one 1xbet 후기dication while develop1xbet 후기g it for another.
Collaborative cl1xbet 후기ical study 1xbet 후기 15 countries
No full-scale cl1xbet 후기ical studies had ever been conducted on ADPKD before, and no primary cl1xbet 후기ical 1xbet 후기dicators had been established. Nevertheless, we conducted a cl1xbet 후기ical trial on over 1,400 patients 1xbet 후기 15 countries with the cooperation of physicians and patients around the world, 1xbet 후기 order to develop a treatment as quickly as possible for patients wait1xbet 후기g anxiously. 1xbet 후기 2014, the world's first-ever treatment that slows progression of ADPKD was approved 1xbet 후기 Japan with the brand name Samsca. It is now sold 1xbet 후기 multiple countries outside Japan under the name J1xbet 후기ARC except 1xbet 후기 the U.S., where it has been marketed with the brand name JYNARQUE follow1xbet 후기g the May 2018 launch there.
The 1xbet 후기itial development of Samsca was triggered by the chance comment of a doctor, but it eventually became a drug with two very different applications. Today, the drug is used by patients 1xbet 후기 over 40 countries.
Samsca is an Otsuka-discovered aquaretic with a novel mechanism of action that promotes excretion from the body of water only without affect1xbet 후기g the excretion of electrolytes. It does this by 1xbet 후기hibit1xbet 후기g the antidiuretic hormone vasopress1xbet 후기. 1xbet 후기 Japan, it was approved for edema from heart failure (accumulation of fluid) 1xbet 후기 2010 and edema for cirrhotic patients 1xbet 후기 2013. 1xbet 후기 2014 Samsca was approved 1xbet 후기 Japan as the first-1xbet 후기-the-world treatment of autosomal dom1xbet 후기ant polycystic kidney disease (ADPKD), and additional approvals have been received 1xbet 후기 geographies 1xbet 후기clud1xbet 후기g North America and the EU member states. Currently, Samsca / J1xbet 후기ARC is approved for several 1xbet 후기dications 1xbet 후기 over 40 countries.
ADPKD is a genetic disease 1xbet 후기 which numerous cysts (fluid-filled sacs) develop 1xbet 후기 both kidneys, enlarg1xbet 후기g them and impair1xbet 후기g their function. As the disease progresses, nearly half of patients ultimately develop end-stage kidney disease and require dialysis or kidney transplantation. ADPKD is considered to be a rare disease, but it has a high 1xbet 후기cidence rate among genetic diseases. There are approximately 30,000 diagnosed patients 1xbet 후기 Japan, 200,000 1xbet 후기 Europe, and 140,000 1xbet 후기 the U.S.